BioDelivery Sciences International

BioDelivery Sciences ("BDSI"®) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. We are utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA®) and other drug delivery technologies to develop and commercialize, either on our own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. Our development strategy focuses on utilization of the Food and Drug Administration's (FDA's) 505(b)(2) approval process. This regulatory pathway allows us to potentially obtain more timely and efficient approval of new formulations of previously approved therapeutics. Our particular area of focus is the development and commercialization of products in the areas of pain management and addiction medicine. These are areas where we believe our drug delivery technologies and products can best be applied to address critical unmet medical needs. Our marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. We look to improve upon existing drugs by enhancing their efficacy and/or ease of administration, or create new therapies, all with the ultimate goal of enhancing patient care.
Show more
TypePublic
HQRaleigh, US
Founded1997
Size (employees)40 (est)
Websitebdsi.com
BioDelivery Sciences International was founded in 1997 and is headquartered in Raleigh, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at BioDelivery Sciences International

Frank E. ODonnell

Frank E. ODonnell

Executive Chairman
Mark A. Sirgo

Mark A. Sirgo

Senior Vice President of Commercialization and Corporate Development
Albert J. Medwar

Albert J. Medwar

Vice President, Marketing and Corporate Development
William B. Stone

William B. Stone

Lead Director
Show more

BioDelivery Sciences International Office Locations

BioDelivery Sciences International has an office in Raleigh
Raleigh, US (HQ)
225 4131 Parklake Ave
Show all (1)
Report incorrect company information

BioDelivery Sciences International Financials and Metrics

BioDelivery Sciences International Revenue

BioDelivery Sciences International's revenue was reported to be $61.99 m in FY, 2017
USD

Revenue (Q2, 2018)

23.5 m

Gross profit (Q2, 2018)

15.5 m

Gross profit margin (Q2, 2018), %

66%

EBIT (Q2, 2018)

(15.4 m)

Market capitalization (20-Sep-2018)

160.8 m

Closing stock price (20-Sep-2018)

2.7

Cash (30-Jun-2018)

55.7 m

EV

154.5 m
BioDelivery Sciences International's current market capitalization is $160.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.4 m38.9 m48.2 m15.5 m62 m

Revenue growth, %

243%24%(68%)

Cost of goods sold

4.9 m8.1 m11.3 m19.5 m

Gross profit

34 m40.1 m4.3 m42.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

3 m20.7 m13.9 m1.8 m13.1 m1.7 m1.2 m3 m5 m3.6 m29.5 m8.7 m11.3 m23.5 m

Cost of goods sold

462.8 k1.1 m2.6 m1.7 m2.6 m4.1 m2.3 m5.6 m4.2 m3.4 m8 m

Gross profit

1.4 m11.9 m(888 k)(464 k)490 k910 k1.3 m23.8 m4.6 m7.9 m15.5 m

Gross profit Margin, %

75%91%(51%)(38%)16%18%35%81%52%70%66%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

23.2 m70.5 m83.6 m32 m21.2 m

Accounts Receivable

2.8 m3.1 m2.5 m3.6 m8.9 m

Inventories

630.7 k2.9 m3.9 m3.4 m6.1 m

Current Assets

26.6 m78.3 m92.5 m43.1 m39.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

38.3 m88.2 m78.4 m85.8 m63.5 m67.7 m54.4 m69.4 m57.5 m44.7 m35.2 m27.5 m12.1 m55.7 m

Accounts Receivable

2.5 m12.6 m205.2 k3 m1.5 m1.4 m2.1 m2.4 m3.1 m7.1 m7.8 m8.1 m9.4 m

Inventories

795.4 k2 m2.6 m1.5 m1.9 m4.8 m4.4 m4 m8.1 m6.6 m5.4 m6.2 m

Current Assets

39.6 m91.4 m92.4 m89.5 m71.7 m73.5 m61.3 m80.2 m67.9 m56.3 m54.4 m44.5 m28.5 m73.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(57.4 m)(54.2 m)(37.7 m)(67.1 m)5.3 m

Depreciation and Amortization

1.3 m1.1 m1.3 m1.4 m693 k

Inventories

(1.8 m)(730 k)(810 k)2.4 m

Accounts Payable

(656.8 k)4.3 m5.1 m(1.3 m)6.6 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(19.2 m)(20.4 m)(18.7 m)(16.5 m)(16 m)(10.7 m)(20.5 m)

Depreciation and Amortization

1.5 m456 k

Inventories

795.4 k2 m2.6 m1.5 m1.9 m4.8 m4.4 m4 m8.1 m716 k(489 k)

Accounts Payable

(3.4 m)(1.1 m)
USDY, 2018

EV/EBIT

-10 x

Financial Leverage

2.9 x
Show all financial metrics
Report incorrect company information

BioDelivery Sciences International Online and Social Media Presence

Embed Graph
Report incorrect company information

BioDelivery Sciences International News and Updates

Report incorrect company information

BioDelivery Sciences International Company Life and Culture

Report incorrect company information